newsfilter
← Latest News
Business Wire·

Genmab Portfolio Prioritization Update

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab's late‑stage pipeline and